These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33822524)

  • 1. Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells.
    de Lima SCG; Fantacini DMC; Batista LC; Silveira RM; Furtado IP; Rossetti R; Brand H; Covas DT; de Souza LEB
    Crit Rev Immunol; 2021; 41(1):41-67. PubMed ID: 33822524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
    de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
    Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
    Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
    J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
    Rafiq S; Hackett CS; Brentjens RJ
    Nat Rev Clin Oncol; 2020 Mar; 17(3):147-167. PubMed ID: 31848460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New CARs on and off the road: challenges and new developments in CAR-T cell therapy.
    Wehrli M; Maus MV
    Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
    Srivastava S; Riddell SR
    J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multipurposing CARs: Same engine, different vehicles.
    Hossian AKMN; Hackett CS; Brentjens RJ; Rafiq S
    Mol Ther; 2022 Apr; 30(4):1381-1395. PubMed ID: 35151842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
    Ramos CA; Dotti G
    Expert Opin Biol Ther; 2011 Jul; 11(7):855-73. PubMed ID: 21463133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
    Qian L; Chen J; Wu X; Jing R; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intelligent cell-based therapies for cancer and autoimmune disorders.
    Chen R; Jing J; Siwko S; Huang Y; Zhou Y
    Curr Opin Biotechnol; 2020 Dec; 66():207-216. PubMed ID: 32956902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
    Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
    Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
    Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
    Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Cell Therapy: Challenges and Optimization.
    Luo M; Zhang H; Zhu L; Xu Q; Gao Q
    Crit Rev Immunol; 2021; 41(1):77-87. PubMed ID: 33822526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.